{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 444487063
| IUPAC_name = (''Z'',''E'')-1-(2-fluorophenyl)-3-(4-hydroxyphenyl)-2-propen-1-one O-[2-(dimethylamino)ethyl]oxime
| image = Eplivanserin structure.svg

<!--Clinical data-->
| tradename =  
| pregnancy_category =  
| legal_status =  
| routes_of_administration = Oral

<!--Pharmacokinetic data-->
| bioavailability =  
| metabolism =  
| elimination_half-life =  
| excretion =  

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 130579-75-8
| CAS_supplemental = <br />{{CAS|130580-02-8}} ([[fumarate]])
| ATC_prefix = none
| ATC_suffix =  
| PubChem = 5493160
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 3CO94WO6DJ
|  ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 13267837
| KEGG = D10006
| KEGG_Ref = {{keggcite|changed|kegg}}
|  StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C19H21FN2O2/c1-22(2)13-14-24-21-19(17-5-3-4-6-18(17)20)12-9-15-7-10-16(23)11-8-15/h3-12,23H,13-14H2,1-2H3/b12-9+,21-19-
|  StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = VAIOZOCLKVMIMN-PRJWTAEASA-N

<!--Chemical data-->
| C=19 | H=21 | F=1 | N=2 | O=2 
| molecular_weight = 328.381 g/mol
| smiles = c2cc(O)ccc2\C=C\C(=N\OCCN(C)C)\c1ccccc1F
}}

'''Eplivanserin''' ('''SR-46,349'''; planned trade name '''Ciltyri''') was an experimental drug for the treatment of [[insomnia]] which was being developed by [[Sanofi Aventis]].<ref name="urlFuture Treatments for Depression, Anxiety, Sleep Disorders, Psychosis, and ADHD -- Neurotransmitter.net">{{cite web | url = http://www.neurotransmitter.net/newdrugs.html | title = Future Treatments for Depression, Anxiety, Sleep Disorders, Psychosis, and ADHD -- Neurotransmitter.net | work = | accessdate = }}</ref>

Sanofi Aventis announced in December 2009 that it was withdrawing its application for approval of eplivanserin from both the [[U.S. Food and Drug Administration]] and the [[European Medicines Agency]].<ref>{{cite news|url=http://english.capital.gr/news.asp?id=876133 |title=Sanofi-Aventis Discontinues Eplivanserin For Insomnia |publisher=Dow Jones & Co |last1=Spencer |first1=Mimosa |last2=Berton |first2=Elena |date=21 December 2009 |accessdate=27 January 2010 |deadurl=yes |archiveurl=https://web.archive.org/web/20110721075618/http://english.capital.gr/news.asp?id=876133 |archivedate=21 July 2011 |df= }}</ref>

== Mechanism of action ==

Eplivanserin is an [[inverse agonist]] on the [[serotonin receptor]] subtype [[5-HT2A|5-HT<sub>2A</sub>]]. In contrast to older [[sedating]] drugs acting on 5-HT<sub>2A</sub> receptors (e.g., [[mirtazapine]], [[clozapine]], [[risperidone]]), eplivanserin has practically no affinity to [[dopamine receptor|dopamine]], [[histamine receptor|histamine]] and [[adrenergic receptor]]s.<ref name="Teergarden">{{cite journal|last=Teergarden|first=BR |author2=Al Shamma, H |author3=Xiong, Y|year=2008|journal=Current Topics in Medicinal Chemistry|volume=8|issue=11|pages=969â€“976|doi=10.2174/156802608784936700|title=5-HT2A Inverse-Agonists for the Treatment of Insomnia|pmid=18673166}}</ref>

== Study results ==

In a placebo controlled [[Phase II clinical trial]] with 351 subjects, eplivanserin reduced the sleep latency by 39 minutes (versus 26 minutes under placebo).<ref name="Teergarden" />

== See also ==
* [[Pimavanserin]]
* [[Volinanserin]]

== References ==
{{Reflist}}

{{Hypnotics}}
{{Serotonergics}}

[[Category:Hypnotics]]
[[Category:Phenols]]
[[Category:Fluoroarenes]]
[[Category:Oximes]]
[[Category:Amines]]


{{sedative-stub}}